---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-23-000010"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:03:14.818596+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q1 net revenue $34.4M (+59% YoY); raises 2023 revenue guidance to $135-155M

## Summary
- Net product revenue $34.3M, up from $21.5M in Q1 2022; net loss $26.2M ($0.18/share) vs $37.6M loss a year ago.
- Raised FY 2023 LUPKYNIS net product revenue guidance to $135-155M, from prior $120-140M.
- 1,731 patients on LUPKYNIS therapy at March 31, 2023, up from 1,071 a year earlier; 466 PSFs added in Q1.
- New method-of-use patent issued; NICE positive recommendation for LUPKYNIS in UK; Swiss regulatory approval received.
- Cash and short-term investments $361.5M at quarter end vs $389.4M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001600620-23-000010
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/0001600620-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/auph-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-23-000010
- JSON: https://secwatch.observer/filing/0001600620-23-000010.json
- Plain text: https://secwatch.observer/filing/0001600620-23-000010.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported first quarter ended March 31, 2023 results: revenue $34.4 million, net income $26.2 million or $0.18 net loss per common share, EPS $0.18 net loss per common share. Guidance raised.
  - Period: first quarter ended March 31, 2023
  - Revenue: $34.4 million
  - Net income: $26.2 million or $0.18 net loss per common share
  - EPS: $0.18 net loss per common share
  - Guidance: raised
  - Result: reported results
  source text: as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/0001600620-23-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.